Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

1. Effect of preoperative inhaled budesonide on pulmonary injury after cardiopulmonary bypass: A randomized pilot study

Effect of preoperative inhaled budesonide on pulmonary injury after cardiopulmonary bypass: A randomized pilot study 30396739 2018 11 06 1097-685X 2018 Oct 06 The Journal of thoracic and cardiovascular surgery J. Thorac. Cardiovasc. Surg. Effect of preoperative inhaled budesonide on pulmonary injury after cardiopulmonary bypass: A randomized pilot study. S0022-5223(18)32518-2 10.1016/j.jtcvs.2018.09.017 Cardiopulmonary bypass can result in lung injury. This prospective, double-blinded (...) , randomized trial aimed to evaluate the protective effect of inhaled budesonide on lung injury after cardiopulmonary bypass. Sixty patients, aged 25 to 65 years, requiring cardiopulmonary bypass were randomized to groups treated with saline or budesonide inhalation preoperatively. The respiratory mechanics were recorded. Bronchoalveolar lavage fluid was collected before cardiopulmonary bypass and after sternal closure. Serum and bronchoalveolar lavage fluid levels of proinflammatory and anti-inflammatory

EvidenceUpdates2018

2. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study 30220648 2018 09 17 1399-3003 52 3 2018 Sep The European respiratory journal Eur. Respir. J. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. 1801334 10.1183/13993003.01334-2018 TELOS compared budesonide (BD)/formoterol fumarate dihydrate (FF) metered dose inhaler (BFF MDI), formulated using innovative co-suspension delivery technology that enables consistent (...) aerosol performance, with its monocomponents and budesonide/formoterol fumarate dihydrate dry powder inhaler (DPI) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), without a requirement for an exacerbation history.In this phase III, double-blind, parallel-group, 24-week study (NCT02766608), patients were randomised to BFF MDI 320/10 µg (n=664), BFF MDI 160/10 µg (n=649), FF MDI 10 µg (n=648), BD MDI 320 µg (n=209) or open-label budesonide/formoterol DPI 400/12 µg

EvidenceUpdates2018

3. Budesonide

Budesonide Top results for budesonide - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for budesonide The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

4. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.

As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. BACKGROUND: Patients with mild asthma often rely on inhaled short-acting β 2 -agonists for symptom relief and have poor adherence to maintenance therapy. Another approach might be for patients to receive a fast-acting reliever plus an inhaled glucocorticoid component on an as-needed basis to address symptoms and exacerbation risk. METHODS: We conducted a 52-week, double-blind, multicenter trial involving patients 12 (...) years of age or older who had mild asthma and were eligible for treatment with regular inhaled glucocorticoids. Patients were randomly assigned to receive twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed or budesonide maintenance therapy with twice-daily budesonide (200 μg) plus terbutaline (0.5 mg) used as needed. The primary analysis compared budesonide-formoterol used as needed with budesonide maintenance therapy with regard

NEJM2018

5. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.

Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. BACKGROUND: In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β 2 -agonist may be an alternative to conventional treatment strategies. METHODS: We conducted a 52-week, double-blind trial involving patients 12 years of age or older with mild asthma. Patients were randomly assigned to one of three regimens: twice-daily placebo plus terbutaline (0.5 mg) used as needed (terbutaline group (...) ), twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed (budesonide-formoterol group), or twice-daily budesonide (200 μg) plus terbutaline used as needed (budesonide maintenance group). The primary objective was to investigate the superiority of as-needed budesonide-formoterol to as-needed terbutaline with regard to electronically recorded weeks with well-controlled asthma. RESULTS: A total of 3849 patients underwent randomization, and 3836 (1277

NEJM2018

6. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma 29301922 2018 01 05 1399-3003 51 1 2018 Jan The European respiratory journal Eur. Respir. J. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. 1701688 10.1183/13993003.01688-2017 Asthma control is often suboptimal in adolescents, but few studies have evaluated asthma treatments in this population.This post hoc analysis assessed the efficacy and safety of budesonide

EvidenceUpdates2018

7. Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia.

Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. BACKGROUND: The long-term effects on neurodevelopment of the use of inhaled glucocorticoids in extremely preterm infants for the prevention or treatment of bronchopulmonary dysplasia are uncertain. METHODS: We randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to receive early (within 24 hours after birth) inhaled budesonide or placebo. The prespecified secondary long-term outcome (...) assigned to budesonide had neurodevelopmental disability, as compared with 165 (51.4%) of 321 infants assigned to placebo (relative risk, adjusted for gestational age, 0.93; 95% confidence interval [CI], 0.80 to 1.09; P=0.40). There was no significant difference in any of the individual components of the prespecified outcome. There were more deaths in the budesonide group than in the placebo group (82 [19.9%] of 413 infants vs. 58 [14.5%] of 400 infants for whom vital status was available; relative

NEJM2018

8. Budesonide (Jorveza) - to treat adults with eosinophilic oesophagitis

Budesonide (Jorveza) - to treat adults with eosinophilic oesophagitis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 09 November 2017 EMA/774645/2017 Assessment report Jorveza International non-proprietary name: budesonide (...) Procedure No. EMEA/H/C/004655/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/774645/2017 Page 2/83 Administrative information Name of the medicinal product: Jorveza Applicant: Dr. Falk Pharma GmbH Leinenweberstr. 5 79108 Freiburg Germany Active substance: budesonide International Non-proprietary Name/Common Name: budesonide Pharmaco-therapeutic group (ATC Code): intestinal antiinflammatory agents

European Medicines Agency - EPARs2018

9. A Randomized Controlled Trial of Budesonide Versus Acetazolamide for the Prevention of Acute Mountain Sickness

A Randomized Controlled Trial of Budesonide Versus Acetazolamide for the Prevention of Acute Mountain Sickness 28668540 2017 07 02 2017 08 01 1555-7162 2017 Jun 28 The American journal of medicine Am. J. Med. Budesonide Versus Acetazolamide for Prevention of Acute Mountain Sickness. S0002-9343(17)30614-9 10.1016/j.amjmed.2017.05.034 Inhaled budesonide has been suggested as a novel prevention for acute mountain sickness. However, efficacy has not been compared with the standard acute mountain (...) sickness prevention medication acetazolamide. This double-blind, randomized, placebo-controlled trial compared inhaled budesonide versus oral acetazolamide versus placebo, starting the morning of ascent from 1240 m (4100 ft) to 3810 m (12,570 ft) over 4 hours. The primary outcome was acute mountain sickness incidence (headache and Lake Louise Questionnaire ≥3 and another symptom). A total of 103 participants were enrolled and completed the study; 33 (32%) received budesonide, 35 (34%) acetazolamide

EvidenceUpdates2017

10. Budesonide-formoterol (Symbicort SMART) - asthma

Budesonide-formoterol (Symbicort SMART) - asthma Published 12 June 2017 Product Update: budesonide/formoterol 100 micrograms/6 micrograms and 200 micrograms/6 micrograms inhalation powder (Symbicort ® SMART ® ) SMC No. (1244/17) AstraZeneca UK Ltd 05 May 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE (...) : following an abbreviated submission budesonide/formoterol (Symbicort ® SMART ® ) is accepted for use within NHS Scotland. Indication under review: the regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting ß 2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” short-acting ß2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting ß2

Scottish Medicines Consortium2017

11. Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma?

Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma? Evidencias en pediatría - Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma? Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset (...) password If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × March 2017. Volume 13. Number 1 Can we use the combination formoterol-budesonide in teenagers with moderate or severe asthma? Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email Confirm email I accept the journal’s

Evidencias en Pediatría2017

12. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. BACKGROUND: IgA nephropathy is thought to be associated with mucosal immune system dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage renal disease in 20-40% of patients within 10-20 years. In this trial (NEFIGAN) we aimed to assess safety and efficacy of a novel targeted-release formulation of budesonide (...) (TRF-budesonide), designed to deliver the drug to the distal ileum in patients with IgA nephropathy. METHODS: We did a randomised, double-blind, placebo-controlled phase 2b trial, comprised of 6-month run-in, 9-month treatment, and 3-month follow-up phases at 62 nephrology clinics across ten European countries. We recruited patients aged at least 18 years with biopsy-confirmed primary IgA nephropathy and persistent proteinuria despite optimised renin-angiotensin system (RAS) blockade. We randomly

Lancet2017

13. Lungs deposition and pharmacokinetic study of submicron budesonide particles in Wistar rats intended for immediate effect in asthma

Lungs deposition and pharmacokinetic study of submicron budesonide particles in Wistar rats intended for immediate effect in asthma 28507469 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Lungs deposition and pharmacokinetic study of submicron budesonide particles in Wistar rats intended for immediate effect in asthma. 236-244 10.17179/excli2016-845 The purpose of the present investigation was to study the aerosolization, lungs deposition and pharmacokinetic study of inhalable submicron (...) particles of budesonide in male Wistar rats. Submicron particles were prepared by antisolvent nanoprecipitation method and freeze-dried to obtain free flowing powder. The freeze-drying process yielded dry powder with desirable aerodynamic properties for inhalation therapy. An in-house model inhaler was designed to deliver medicine to lungs, optimized at dose level of 10 mg for 30 sec of fluidization. The in vitro aerosolization study demonstrates that submicron particles dissolve faster with improved

EXCLI journal2017 Full Text: Link to full Text with Trip Pro

14. CORTIMENT (budesonide), corticosteroid for local use

CORTIMENT (budesonide), corticosteroid for local use Haute Autorité de Santé - CORTIMENT (budésonide), corticoïde d’action locale Contribuer à la régulation par la qualité et l'efficience Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments CORTIMENT (budésonide), corticoïde d’action locale Substance active (DCI) budésonide GASTRO-ENTEROLOGIE - Nouveau médicament Nature de la demande Inscription Avis de la CT du 25

Haute Autorite de sante2017

15. Budesonide (Cortiment) - for induction of remission in patients with mild to moderate active ulcerative colitis (UC)

Budesonide (Cortiment) - for induction of remission in patients with mild to moderate active ulcerative colitis (UC)

Scottish Medicines Consortium2016

16. Budesonide-formoterol (Symbicort) - Treatment of patients with chronic obstructive pulmonary disease (COPD)

Budesonide-formoterol (Symbicort) - Treatment of patients with chronic obstructive pulmonary disease (COPD) Published 10 October 2016 Statement of Advice: budesonide/formoterol 200 micrograms/6 Inhalation powder and 400 micrograms/12 Inhalation powder (Symbicort Turbohaler ® ) budesonide/formoterol 200 micrograms/6 micrograms per actuation, pressurised inhalation, suspension (Symbicort ® ) (No: 1198/16) AstraZeneca UK Limited 09 September 2016 ADVICE: in the absence of a submission from (...) the holder of the marketing authorisation budesonide/formoterol inhalation powder (Symbicort Turbohaler ® ) and pressurised inhalation, suspension (Symbicort ® ) are not recommended for use within NHS Scotland. Indication under review: Treatment of patients with chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV 1 ) 50% to 70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy. The holder of the marketing

Scottish Medicines Consortium2016

17. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone.

Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. BACKGROUND: Concerns remain about the safety of adding long-acting β2-agonists to inhaled glucocorticoids for the treatment of asthma. In a postmarketing safety study mandated by the Food and Drug Administration, we evaluated whether the addition of formoterol to budesonide maintenance therapy increased the risk of serious asthma-related events in patients with asthma. METHODS: In this multicenter, double-blind, 26-week (...) study, we randomly assigned patients, 12 years of age or older, who had persistent asthma, were receiving daily asthma medication, and had had one to four asthma exacerbations in the previous year to receive budesonide-formoterol or budesonide alone. Patients with a history of life-threatening asthma were excluded. The primary end point was the first serious asthma-related event (a composite of adjudicated death, intubation, and hospitalization), as assessed in a time-to-event analysis

NEJM2016

18. Budesonide (TBC)

Budesonide (TBC) Budesonide | CADTH.ca Find the information you need Budesonide Budesonide Last Updated: Result type: Reports Project Number: SR0491-000 Product Line: Generic Name: Budesonide Brand Name: Cortiment Manufacturer: Ferring Inc. Indications: Ulcerative Colitis Submission Type: New Indication Project Status: Complete Date Recommendation Issued: March 22, 2017 Recommendation Type: Do not reimburse Files Follow us: © 2017 Canadian Agency for Drugs and Technologies in Health Get our

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2016

19. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia

Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia 26351971 2016 01 01 2016 05 04 2016 01 01 1535-4970 193 1 2016 Jan 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. 86-95 10.1164/rccm.201505-0861OC Bronchopulmonary dysplasia (BPD) is an important complication of mechanical ventilation in preterm infants (...) , and no definite therapy can eliminate this complication. Pulmonary inflammation plays a crucial role in its pathogenesis, and glucocorticoid is one potential therapy to prevent BPD. To compare the effect of intratracheal administration of surfactant/budesonide with that of surfactant alone on the incidence of death or BPD. A clinical trial was conducted in three tertiary neonatal centers in the United States and Taiwan, in which 265 very-low-birth-weight infants with severe respiratory distress syndrome who

EvidenceUpdates2016

20. Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia.

Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. BACKGROUND: Systemic glucocorticoids reduce the incidence of bronchopulmonary dysplasia among extremely preterm infants, but they may compromise brain development. The effects of inhaled glucocorticoids on outcomes in these infants are unclear. METHODS: We randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to early (within 24 hours after birth) inhaled budesonide or placebo until (...) they no longer required oxygen and positive-pressure support or until they reached a postmenstrual age of 32 weeks 0 days. The primary outcome was death or bronchopulmonary dysplasia, confirmed by means of standardized oxygen-saturation monitoring, at a postmenstrual age of 36 weeks. RESULTS: A total of 175 of 437 infants assigned to budesonide for whom adequate data were available (40.0%), as compared with 194 of 419 infants assigned to placebo for whom adequate data were available (46.3%), died or had

NEJM2015 Full Text: Link to full Text with Trip Pro